Trial Profile
Open-label Biomarker Study of Rosuvastatin (Crestor) for the Treatment of Patients With Friedreich Ataxia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Friedreich's ataxia
- Focus Biomarker; Pharmacodynamics
- 08 Jan 2018 Status changed from recruiting to completed.
- 15 Mar 2017 Phase changed from 0 to early phase 1.
- 06 Jul 2016 Status changed from not yet recruiting to recruiting.